Melanoma: Antibiotics & Energy Inhibitors Kill Cancer Cells
- the most aggressive forms of melanoma, the deadliest type of skin cancer, may have a critical weakness: overactive mitochondria.
- The findings, published in Cancer, highlight a potential new avenue for melanoma treatment.
- When researchers blocked these pathways in lab-grown melanoma cells, the cells were either halted or killed.
Scientists have made a breakthrough: specific antibiotics and energy inhibitors can kill aggressive melanoma cells by targeting overactive mitochondria. This exciting melanoma research shows that existing drugs might offer new hope in the fight against . Researchers discovered that these cancer cells rely heavily on mitochondrial processes, making them vulnerable. By disrupting these processes,the drugs effectively eliminated melanoma cells in the lab,while leaving healthy cells unharmed. This innovative approach could lead to more personalized treatment strategies for and other cancers. News Directory 3 reports on this major step forward. Discover what’s next …
Melanoma Research: Targeting Mitochondria with Existing Drugs
Updated June 23, 2025
the most aggressive forms of melanoma, the deadliest type of skin cancer, may have a critical weakness: overactive mitochondria. Researchers have found that these melanomas excessively use two key mitochondrial processes. Blocking these pathways with existing drugs proved effective in killing melanoma cells in laboratory settings.
The findings, published in Cancer, highlight a potential new avenue for melanoma treatment. By mapping proteins in 151 tumor and normal skin samples, the team discovered that aggressive melanomas heavily rely on the machinery that builds mitochondrial proteins and the mitochondrial system that converts nutrients into energy.
When researchers blocked these pathways in lab-grown melanoma cells, the cells were either halted or killed. This was achieved using antibiotics,originally designed to block bacterial protein synthesis (similar to mitochondrial machinery),and specialized energy-production inhibitors. Notably, non-cancerous skin cells remained largely unaffected, suggesting the safety and specificity of this approach to .
“This revelation identifies melanoma’s excessive reliance on mitochondrial energy as its achilles’ heel,” said Dr. Jeovanis gil, of Lund University in Sweden, the study’s senior author. He added that this reveals “a therapeutic vulnerability that we can exploit with existing drugs.”
Gil suggests that combining mitochondrial blockers with current standard treatments could cut off a major escape route that cancers use to resist therapy and recur. The mitochondrial-protein signature discovered by his team can be measured in routine biopsy material, potentially serving as a biomarker to identify patients most likely to benefit from mitochondrial-targeted therapies for .
These findings represent a step toward precision medicine in melanoma, enabling clinicians to tailor treatments to each patient’s tumor biology. As mitochondrial rewiring fuels resistance in many cancers, success in melanoma could pave the way for similar personalized combination strategies in other difficult-to-treat cancers.
What’s next
Researchers plan to further investigate the effectiveness of mitochondrial-targeted therapies in clinical trials, exploring their potential to improve outcomes for melanoma patients and those with other cancers.